Hereditary Cancer Testing Market Size, Share & Trends Analysis Report By Cancer, By Technology (Cytogenetic, Biochemical, Molecular Testing), By Test Type (Predictive Testing, Diagnostic Testing), By End Use, By Region, And Segment Forecasts, 2025 - 2033

Hereditary Cancer Testing Market Summary

The global hereditary cancer testing market size was estimated at USD 4.67 billion in 2024 and is projected to reach USD 14.45 billion by 2033, growing at a CAGR of 13.76% from 2025 to 2033. The demand for hereditary cancer testing is increasing due to technological advancements in genetic testing for cancer detection, integration with precision medicine, and growing awareness through public and government initiatives.

In addition, the rising prevalence of cancer diseases amongst the population is augmenting the adoption of hereditary cancer testing. According to the National Cancer Institute, hereditary cancer, caused by inherited genetic changes, accounts for 10% of all other cancer types. Hereditary cancer is passed on to coming generations as defective familial mutations in the genes, concomitantly increasing the risk of cancer. Hence, there arises a growing need among the people for early detection and for mitigating cancer symptoms.

Advancements in genetic testing technologies, particularly next-generation sequencing (NGS), have significantly improved the accuracy and accessibility of hereditary cancer testing. Traditional methods lack efficiency and are time-consuming, which may prolong the treatment duration thereafter. One such testing technology is the next-generation sequencing (NGS), which can simultaneously detect millions of copies of DNA in a gene within a short span of time, allowing comprehensive profiling of multiple genes and mutations in a single test. For example, Illumina’s NovaSeq X platform offers high-throughput sequencing for analyzing large sequences of data and diagnose the condition of diseases. The innovations in genetic testing facilitate early detection of hereditary cancer mutations, guide personalized treatment plans, and monitor disease progression non-invasively. Thus, progress in oncology medicine by integration of early cancer detection systems is transforming the perspective to advanced technologies rather than traditional testing methods.

Hereditary testing plays a pivotal role in precision medicine by enabling the identification of genetic mutations that influence cancer risk and treatment response. The basis of precision medicine lies in understanding the effects of alterations in certain genes in cancer. Precision medicine is transforming cancer care to tailor tests and treatments based on individual patient characteristics. It helps identify people at high risk for cancer, allowing early interventions to reduce their risk. It also aids in detecting certain cancers at an early stage and ensures accurate diagnosis of specific cancer types. Additionally, it allows ongoing evaluation of how well a treatment is working, enabling adjustments to improve outcomes. This personalized approach improves survival rates and quality of life for cancer patients by moving beyond one-size-fits-all therapies to targeted, patient-specific care.

Growing awareness through public and government initiatives plays a crucial role in expanding hereditary cancer testing. Government efforts, for example, in February 2024, the National Institutes of Health (NIH) launched the Cancer Screening Research Network (CSRN), a clinical trials network aimed at evaluating emerging cancer screening technologies, including multi-cancer detection (MCD) tests. This initiative supports the Biden-Harris administration’s Cancer Moonshot by focusing on identifying cancers earlier, when treatment is more effective.

The National Institutes of Health (NIH) is also working continuously in prevention and screening for five major types of cancer: breast, cervical, colorectal, lung, and prostate, in order to save lives. Due to its initiatives, as of December 2024, 4.75 million deaths have been averted. Furthermore, several campaigns and online resources have raised awareness among the people for hereditary cancer testing. These combined efforts aim to empower individuals with knowledge, encourage timely testing, and support preventive care, ultimately reducing cancer incidence and improving outcomes across diverse populations.

Global Hereditary Cancer Testing Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global hereditary cancer testing market report based on cancer, technology, test type, end use, and region:

• Cancer Outlook (Revenue, USD Million, 2021 - 2033)
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Cervical Cancer
• Ovarian Cancer
• Prostate Cancer
• Stomach/Gastric Cancer
• Melanoma
• Sarcoma
• Uterine Cancer
• Pancreatic Cancer
• Others
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Cytogenetic
• Biochemical
• Molecular Testing
• Test Type Outlook (Revenue, USD Million, 2021 - 2033)
• Predictive Testing
• Diagnostic Testing
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Diagnostic Centers
• Hospitals
• Clinics
• Regional Outlook (Revenue in USD Million, 2021 - 2033)
• North America
• U.S.
• Canada
• Mexico
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Sweden
• Denmark
• Norway
• Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• Thailand
• Latin America
• Brazil
• Argentina
• Middle East and Africa
• Saudi Arabia
• South Africa
• UAE
• Kuwait

Please note The report will be delivered in 2-3 business days upon order notification. Show more